A group of individual investors has acquired Saneca/Slovakofarma Hlohovec
March 2013 — In this asset deal, a group of private investors has acquired Saneca's cosmetic products portfolio and its pharmaceutical manufacturing plant in Slovakia, from Sanofi. Financial terms of this transaction have not been disclosed.
Saneca (originally Zentiva Hlohovec) is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns portfolio of cosmetic and generic products.
Sanofi is a global integrated healthcare leader engaged in the research, development, manufacturing and marketing of therapeutic solutions.
Our role in the transaction
Oaklins' team in Slovakia advised the buyer in this transaction. The process included due diligence, valuation, negotiation of transaction terms, and selection of new management in the newly purchased entity.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more